U.S. markets closed
  • S&P Futures

    4,532.75
    -3.75 (-0.08%)
     
  • Dow Futures

    35,527.00
    -30.00 (-0.08%)
     
  • Nasdaq Futures

    15,329.25
    -11.75 (-0.08%)
     
  • Russell 2000 Futures

    2,285.90
    -2.90 (-0.13%)
     
  • Crude Oil

    84.45
    +0.69 (+0.82%)
     
  • Gold

    1,794.10
    -2.20 (-0.12%)
     
  • Silver

    24.39
    -0.06 (-0.24%)
     
  • EUR/USD

    1.1647
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3767
    +0.0008 (+0.06%)
     
  • USD/JPY

    113.6460
    +0.1860 (+0.16%)
     
  • BTC-USD

    61,706.57
    +645.84 (+1.06%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,624.18
    -180.67 (-0.63%)
     

Janssen Shares Erdafitinib Combo Therapy Data In Bladder Cancer

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Janssen, a unit of Johnson & Johnson (NYSE: JNJ), announced results from the Phase 1b/2 NORSE study evaluating Balversa (erdafitinib) plus cetrelimab combination.

  • The trial included patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin.

  • The results were highlighted at the European Society for Medical Oncology (ESMO21) Annual Congress 2021.

  • The investigator-assessed objective response rate (ORR) in 19 patients treated with Balversa plus cetrelimab was 68%, of which 21% were complete responses (CR), and 47% were partial responses (PR).

  • The disease control rate (DCR) was 90%.

  • The ORR in 18 patients treated with Balversa monotherapy was 33%, in which one patient showed a CR and 28% (n=5) were partial responses.

  • The DCR was 100%.

  • Price Action: JNJ shares are down 0.61% at $164.22 during the market session on the last check Friday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.